ArticleScientific reports2025
Achieved targeted heart rate following ivabradine therapy correlates with left ventricular reverse remodeling in non-ischemic dilated cardiomyopathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The effect of ivabradine on left ventricular reverse remodeling (LVRR) in heart failure with reduced ejection fraction and its correlation with achieved heart rate (HR) by ivabradine in non-ischemic dilated cardiomyopathy (NIDCM) remain uncertain. A retrospective analysis of 255 sinus rhythm NIDCM patients at a tertiary center (2012-2021) were categorized into four groups based on the ivabradine use (Iva+/-) and achieved HR at 1-year (HR+/-). The HR cut-off of 70 bpm was determined via receiver operating characteristic curve analysis for LVRR, defined as an absolute ≥ 10% improvement in LV ejection fraction (LVEF) from baseline, with a final LVEF ≥ 40%. LVRR incidence at 1-year was, 46.8% in Iva-/HR70+, 46.6% in Iva-/HR70-, 62.9% Iva+/HR70+ and 71.1% in Iva+/HR70-. Ivabradine treated patients with HR < 70 bpm had higher incidence of LVRR than those without ivabradine (Iva+/HR70-vs. Iva-/HR70+, OR 4.85, 95%CI 1.97-11.96 P = 0.001; Iva+/HR70-vs. Iva-/HR70-, OR 3.60, 95% CI 1.41-9.18, P = 0.007) after adjustment for known predictors in a multivariate model. Consistent adherence to beta-blockers and ivabradine, along with guideline-directed medical therapy (GDMT) for HF, and sex were identified as independent predictors of LVRR. Ivabradine therapy achieving HR < 70 bpm correlated with increased LVRR incidence in NIDCM patients, underscoring the role of ivabradine in HR reduction adjunctive to GDMT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.